Details for Patent: 12,403,173

Which drugs does patent 12,403,173 protect, and when does it expire?

Patent 12,403,173 protects MICAFUNGIN IN SODIUM CHLORIDE 0.9% and is included in one NDA.

This patent has eleven patent family members in ten countries.

Summary for Patent: 12,403,173

Title:	Micafungin compositions
Abstract:	An aqueous pharmaceutical composition suitable for parenteral administration and having enhanced storage stability includes between about 0.1 mg/mL and about 40 mg/mL micafungin; (ii) between about 0.1 mM and 400 mM buffering agent; and (iii) between about 0 mg/mL and about 500 mg/mL tonicity adjusting agent, wherein the pH of the composition is between about 3.0 and 7.0, for example, between about 3.5 and 7.0.
Inventor(s):	Sydney J. Cope, Christine L. Rebbeck, Mark J. Doty
Assignee:	Baxter Healthcare SA , Baxter International Inc
Application Number:	US15/843,634
Patent Claim Types: see list of patent claims	Composition; Formulation; Dosage form;

Drugs Protected by US Patent 12,403,173

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Baxter Hlthcare Corp	MICAFUNGIN IN SODIUM CHLORIDE 0.9%	micafungin sodium	SOLUTION;INTRAVENOUS	216142-001	Sep 29, 2023		RX	Yes	Yes			Y
Baxter Hlthcare Corp	MICAFUNGIN IN SODIUM CHLORIDE 0.9%	micafungin sodium	SOLUTION;INTRAVENOUS	216142-002	Sep 29, 2023		RX	Yes	Yes			Y
Baxter Hlthcare Corp	MICAFUNGIN IN SODIUM CHLORIDE 0.9%	micafungin sodium	SOLUTION;INTRAVENOUS	216142-003	Sep 29, 2023		RX	Yes	Yes			Y

International Family Members for US Patent 12,403,173

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2017376960
Denmark	3554474
European Patent Office	3554474
Spain	2972008
Finland	3554474
Hungary	E066069
Japan	2020510619